Huadong Medicine's subsidiary gets trial approval for HDM2020

Huadong Medicine (SZSE:000963) announced today that its wholly-owned subsidiary, Hangzhou Sino-American Donghua Pharmaceutical Co., Ltd., has received a clinical trial approval from China's National Medical Products Administration (NMPA) for its innovative drug, HDM2020. The drug, classified as a Class 1 therapeutic biological product, is intended for the treatment of advanced solid tumors. HDM2020 is an antibody-drug conjugate (ADC) targeting Fibroblast Growth Factor Receptor 2b (FGFR2b). Preclinical studies have demonstrated strong anti-tumor activity in models of gastric cancer and squamous non-small cell lung cancer. The company emphasizes that while this approval is a significant milestone, the drug's progress toward commercialization is subject to various risks and uncertainties, including clinical trial outcomes, regulatory approvals, and market competition. Huadong Medicine will continue to advance the drug's development and fulfill its disclosure obligations.